Pfizer's stock has been under extensive analysis by investors and market experts amidst some staggering activities in the bio-tech market. TV personality Jim Cramer expressed bearish sentiment on drug stocks, labelling Pfizer's state as continuous suffering. Pharmaceutical company Novo Nordisk engages in a bidding war with Pfizer over the obesity drug company Metsera, an aggressive move that has led to varied speculations and reactions in the market. Insider trading activities have seen significant buys and sells of Pfizer shares by various investment firms, indicating a mixed sentiment. The comprehensive Q3 earnings for Pfizer are eagerly anticipated by investors with advice ranging from buying to holding to selling Pfizer's stock. Several expert analyses suggest Pfizer's stocks are undervalued despite recent performance trends. A lawsuit has been filed by Pfizer against Novo and Metsera over the controversial bid. The spotlight is also on projections of where Pfizer would stand in five years with a predicted mix in pipeline expansion news. The reaction to Pfizer's massive Trump deal varies with some labeling it as good news and others asking for a cautious approach. Pharmaceutical giants AstraZeneca and Eli Lilly may be potential next deals after Pfizer.
Pfizer Stocks News Analytics from Wed, 13 Aug 2025 07:00:00 GMT to Sat, 01 Nov 2025 11:09:10 GMT -
Rating 5
- Innovation -3
- Information 6
- Rumor 1
